Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1919 1
1923 1
1924 1
1925 2
1928 2
1945 2
1946 7
1947 12
1948 12
1949 9
1950 5
1951 14
1952 12
1953 20
1954 16
1955 13
1956 19
1957 9
1958 6
1959 13
1960 19
1961 20
1962 27
1963 29
1964 30
1965 48
1966 59
1967 92
1968 117
1969 114
1970 128
1971 157
1972 194
1973 236
1974 256
1975 951
1976 1087
1977 1097
1978 1208
1979 1411
1980 1613
1981 1871
1982 1984
1983 2635
1984 2894
1985 3318
1986 3696
1987 4258
1988 4674
1989 6075
1990 6611
1991 7557
1992 8359
1993 9600
1994 10789
1995 12249
1996 13758
1997 15111
1998 16973
1999 19122
2000 21988
2001 24364
2002 27217
2003 30938
2004 36177
2005 40417
2006 45876
2007 50466
2008 55927
2009 60585
2010 69664
2011 79197
2012 88215
2013 96388
2014 104799
2015 113270
2016 120179
2017 127267
2018 135316
2019 146179
2020 169257
2021 190244
2022 192526
2023 188980
2024 211676
2025 279559
2026 228683
2027 229

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,783,910 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 16618118
Page 1
Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia.
Wu X, Wang F, Yang X, Gong Y, Niu T, Chu B, Qu Y, Qian Z. Wu X, et al. Small. 2024 Oct;20(42):e2403409. doi: 10.1002/smll.202403409. Epub 2024 Jun 27. Small. 2024. PMID: 38934349 Review.
Conventional therapies, including chemotherapy, hematopoietic stem cell transplantation (HSCT), immune therapy, and targeted agents, have unsatisfactory outcomes for AML patients due to drug toxicity, off-target effects, drug resistance, drug side effects, and AML r …
Conventional therapies, including chemotherapy, hematopoietic stem cell transplantation (HSCT), immune therapy, and targeted agents, …
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer.
Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. Saddawi-Konefka R, et al. Cancer J. 2022 Sep-Oct 01;28(5):339-345. doi: 10.1097/PPO.0000000000000622. Cancer J. 2022. PMID: 36165721 Free PMC article. Review.
This review highlights the HER2 and HER3 signaling pathways and clinical efforts to target these receptors and their aberrant signaling to treat head and neck squamous cell carcinomas and other head and neck malignancies, including salivary gland carcinomas. This includes …
This review highlights the HER2 and HER3 signaling pathways and clinical efforts to target these receptors and their aberrant signali …
Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics.
Huang M, Wei F, Cao J, Jiang H. Huang M, et al. Bioorg Chem. 2025 Oct;165:108985. doi: 10.1016/j.bioorg.2025.108985. Epub 2025 Sep 12. Bioorg Chem. 2025. PMID: 40946517 Review.
Traditional treatment modalities, including chemotherapy and molecular targeted therapies, often face challenges such as drug resistance, limited targetability, and systemic toxicity. The emergence of proteolysis-targeting chimeras (PROTACs) has opened a new …
Traditional treatment modalities, including chemotherapy and molecular targeted therapies, often face challenges such as drug resista …
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K. Liu L, et al. Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046. Int J Mol Sci. 2024. PMID: 39337530 Free PMC article. Review.
New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in adva …
New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate r …
Targeting the undruggables-the power of protein degraders.
Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, Sheng C, Ding K, Rao Y. Zhang C, et al. Sci Bull (Beijing). 2024 Jun 15;69(11):1776-1797. doi: 10.1016/j.scib.2024.03.056. Epub 2024 Mar 29. Sci Bull (Beijing). 2024. PMID: 38614856 Free article. Review.
Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional methods or have not yet been targeted, but are of great clinical significance. ...Among them, targeted protein degradation te …
Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional …
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C. Domostegui A, et al. Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g. Chem Soc Rev. 2022. PMID: 35723413 Review.
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubiquitin ligase, prompting the proteasomal degradation of the former. This and other pharmacological strategies of targeted protein deg …
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubi …
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. Corre I, et al. Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976. Cells. 2020. PMID: 32326444 Free PMC article. Review.
Consequently, efforts to improve treatments using targeted therapies have faced this lack of specific osteosarcoma targets. Nevertheless, these tumors are inextricably linked to their local microenvironment, composed of bone, stromal, vascular and immune cells and t …
Consequently, efforts to improve treatments using targeted therapies have faced this lack of specific osteosarcoma targets. Ne …
Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Setton J, et al. Cancer Discov. 2021 Jul;11(7):1626-1635. doi: 10.1158/2159-8290.CD-20-1503. Epub 2021 Apr 1. Cancer Discov. 2021. PMID: 33795234 Free PMC article. Review.
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a wide array of novel SL drug targets. Here, we review concepts and lessons emerging from first-generation trials aimed at testing SL …
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a …
Biomarkers and targeted therapy for cancer stem cells.
Liu Y, Wang H. Liu Y, et al. Trends Pharmacol Sci. 2024 Jan;45(1):56-66. doi: 10.1016/j.tips.2023.11.006. Epub 2023 Dec 9. Trends Pharmacol Sci. 2024. PMID: 38071088 Free PMC article. Review.
For these reasons, extensive efforts have been made to identify and target CSCs to potentially improve the antitumor efficacy of therapeutics. While progress has been made to uncover certain CSC-associated biomarkers, the identification of CSC-specific markers, especially …
For these reasons, extensive efforts have been made to identify and target CSCs to potentially improve the antitumor efficacy of ther …
Electrophilic warheads in covalent drug discovery: an overview.
Péczka N, Orgován Z, Ábrányi-Balogh P, Keserű GM. Péczka N, et al. Expert Opin Drug Discov. 2022 Apr;17(4):413-422. doi: 10.1080/17460441.2022.2034783. Epub 2022 Feb 6. Expert Opin Drug Discov. 2022. PMID: 35129005 Review.
The warheads are discussed by targeted residues, mechanism and selectivity, and analyzed through three different datasets including our collection of warheads, the CovPDB database, and the FDA approved covalent drugs. ...However, versatile, selective warheads are not avail …
The warheads are discussed by targeted residues, mechanism and selectivity, and analyzed through three different datasets including o …
2,783,910 results
You have reached the last available page of results. Please see the User Guide for more information.